TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04469361

Intervention type: OTHER
Intervention: Navicular drop measurement
Description: The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.

Intervention type: OTHER
Intervention: Navicular drop measurement
Description: The difference in navicular height between sitting and standing positions was recorded (mm) as the amount of navicular drop.

Intervention type: OTHER
Intervention: Measurement of venous return parameters in supine
Description: Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position

Intervention type: OTHER
Intervention: Measurement of venous return parameters in supine
Description: Venous return parameters of posterior tibial vein was measured when participant applied force equivalent to their own body weight on plantar surface of their right leg in supine position

Intervention type: OTHER
Intervention: Measurement of venous return parameters in standing
Description: In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.

Intervention type: OTHER
Intervention: Measurement of venous return parameters in standing
Description: In standing, venous return parameters was measured of posterior tibial vein when participants shift all of their weight to the right leg for 3 second with their leg muscles as relaxed as possible and their knee joint in full extension.

Intervention type: OTHER
Intervention: measurement of midfoot pressure distrubition
Description: In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg

Intervention type: OTHER
Intervention: measurement of midfoot pressure distrubition
Description: In standing, midfoot pressure distrubution was measured when participants shift all of their weight to the right leg
Study: NCT01038271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Palliative Care Group
Description: Participant is referred to the Palliative Care Team at any time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Palliative Care Intervention
Description: Participant meets with the Palliative Care Team within 3 weeks of being randomized
Study: NCT01978431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocaine hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylphenidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Study: NCT04169295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gynecologists' feedback on ART-Birth rates
Description: At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
Study: NCT02357576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20% I.V. Fat Emulsion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20% I.V. Fat Emulsion
Study: NCT06651125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: Patients in the Adapted Physical Activity arm realized a 12-weeks supervised exercise program. The supervised PA intervention consisted of two sessions per week. Each session lasted one hour and was divided into 30 minutes of aerobic exercise using an ergometer (treadmill and/or bicycle), followed by 30 minutes of resistance exercises involving major muscle groups, with or without small equipment such as dumbbells, resistance bands, and balls. The exercise regimen was carried out at an intensity ranging from 50% to 70% of the heart rate reserve, with a rate of perceived exertion (RPE) set at 4 on a Borg scale of 0 to 10. A total of 24 sessions were planned. There was also the option to incorporate a 45-minute session of moderate-intensity water aerobics into the weekly routine.
Study: NCT01987323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of liposomal latanoprost
Study: NCT03101475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic body radiation therapy (SBRT)
Description: delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
Study: NCT03586739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computerized tomography scan (CT-scan)
Description: a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital angiography
Description: In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital angiography
Description: In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short Form-36 (SF-36) questionnaire
Description: The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Form-36 (SF-36) questionnaire
Description: The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
Study: NCT03101475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
Study: NCT01567176

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
Study: NCT03829735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
Study: NCT03081416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intranasal ketamine administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Standard therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benadryl
Description: Standard therapy
Study: NCT01100008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: MRI cardiac and pulmonary with gadolinium
Study: NCT03661515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: According to escalation level:~* Level -1: Selinexor 40 mg/day, once weekly~* Level 1: Selinexor 60 mg/day, once weekly~* Level 2: Selinexor 80 mg/day, once weekly~* Level 3: Selinexor 100 mg/day, once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: fludarabine 30 mg/m2/day intravenously on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: idarubicin 10 mg/m2/day intravenously on days 1 to 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: cytarabine 2 g/m2/day intravenously on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
Study: NCT00261716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPS
Description: Individual Placement and Support Evidence based supported employment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS
Description: Individual Placement and Support Evidence based supported employment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IE
Description: Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOMI
Description: Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
Study: NCT01800916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Adhesive baseplate A
Description: Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Adhesive baseplate A
Description: Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
Study: NCT02012322

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months
Study: NCT01800916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Adhesive baseplate B
Description: Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Adhesive baseplate B
Description: Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Adhesive baseplate C
Description: Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Adhesive baseplate C
Description: Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura 1-Piece
Description: SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura 1-Piece
Description: SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura 1-Piece
Description: SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
Study: NCT06095843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of dental implants
Description: placement of dental implants in mandibular reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of dental implants
Description: placement of dental implants in mandibular reconstruction.
Study: NCT01514552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry gummy
Description: Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control gummy
Description: Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
Study: NCT04820816

Intervention type: OTHER
Intervention: pelvic tilt effect on balance, sensory integration and risk of fall
Description: BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test

Intervention type: OTHER
Intervention: pelvic tilt effect on balance, sensory integration and risk of fall
Description: BIODEX balance system, Limits of stability test, Risk of Fall test, m-CTSIB test
Study: NCT03746821

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Biotin
Description: Biotin supplements (2) to be taken daily
Study: NCT01988571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg tablet taken by mouth each morning for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg tablet taken by mouth each morning for 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet taken each morning orally for 24 months.
Study: NCT01416883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1
Study: NCT02129361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Screening and Brief Intervention (Adapted SBI)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening & Education Attention Control
Study: NCT02128295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric breast pump - A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric breast pump - A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric breast pump - B

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric breast pump - B
Study: NCT02151708

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: motilitone
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: motilitone
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
Study: NCT02187302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (Investigator Choice)
Study: NCT02012322

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months
Study: NCT02493634

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pressure gradient measurement
Description: A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.

Intervention type: DEVICE
Group type: OTHER
Intervention: MRWire
Study: NCT02117063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go Girls! Fitness Support Group
Description: Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
Study: NCT00805116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whale blubber oil
Description: 15 ml/day for 4 months, divided on dosage morning and evening, orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod liver oil
Description: 15 ml/day for 4 months, divided on dosage morning and evening, taken orally
Study: NCT04194775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nofazinlimab (CS1003)+Lenvatinib
Description: Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nofazinlimab (CS1003) Placebo+Lenvatinib
Description: Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
Study: NCT00638703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oxalobacter formigenes
Description: NLT (not less than) 10\^7 CFU Oxalobacter formigenes twice daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03456089

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urodynamics Testing
Description: Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
Study: NCT04114903

Intervention type: OTHER
Intervention: Study A: Single use of cannabis flower product
Description: Participants are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).

Intervention type: OTHER
Intervention: Study B: Ad libitum cannabis use for four weeks or no cannabis use
Description: Participants choose whether to use a cannabis flower product ad libitum for four weeks or to not use cannabis for four weeks. Participants who choose to use cannabis are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
Study: NCT01182506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training Program
Description: Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home.
Study: NCT02012322

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period
Study: NCT03524027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Vertebral Column Resection (PVCR)
Description: Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
Study: NCT01148953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-TTR01
Description: Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline (0.9% NaCl)
Description: Calculated volume to match active comparator
Study: NCT02719158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg ciprofloxacin
Description: Single administration of OTO-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg ciprofloxacin
Description: Single administration of OTO-201

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT02796807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT
Study: NCT00556595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary electrophysiological approach
Description: primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary anatomical approach
Description: primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
Study: NCT01234467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles